Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Horizon Discovery, Mammoth Biosciences Sign Second CRISPR Tools Development Agreement

Horizon Discovery, Mammoth Biosciences Sign Second CRISPR Tools Development Agreement

Jan 13, 2020
|
staff reporter

NEW YORK – Horizon Discovery announced on Monday that it has signed a collaboration and license agreement with Mammoth Biosciences to develop a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

What's Popular?

In Business News

  1. LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

  2. Color Gears Up to Enter COVID-19 Testing Space

  3. A. Menarini to Distribute Credo Diagnostics Coronavirus Assay Kit, Respiratory Infection Assays

  4. Ipsum Diagnostics Coronavirus Test Gets FDA Emergency Use Authorization

  5. Bionano Prices $18M Stock, Warrant Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.